Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stryker Sales Aided By Expanding Domestic Orthopedic Implant Business

This article was originally published in The Gray Sheet

Executive Summary

Stryker is experiencing a "resurgence" in its U.S. orthopedics division, aided by double-digit growth of reconstructive implant sales

You may also be interested in...



S&N’s Potential Biomet Acquisition Would Create Top-Tier Ortho Player

Smith & Nephew is weighing a potential acquisition of Biomet that would create a top-tier reconstructive orthopedic implant player and tighten competition with rivals Zimmer, Stryker and Johnson & Johnson/DePuy

S&N’s Potential Biomet Acquisition Would Create Top-Tier Ortho Player

Smith & Nephew is weighing a potential acquisition of Biomet that would create a top-tier reconstructive orthopedic implant player and tighten competition with rivals Zimmer, Stryker and Johnson & Johnson/DePuy

Stryker expands hip offerings

September global launch of Stryker's LFIT anatomic femoral heads with X3 polyethylene liners follows 510(k) clearance, announced Aug. 25. Designed to maximize hip stability, the alternative to metal-on-metal bearings uses low friction ion treatment technology and is "anatomically sized for more natural hip performance," Stryker claims. "Up until now, metal-on-metal options in larger sizes only met the needs of a subset of the total hip population"...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel